| [18 F]-Fludarabine Positron Emission Tomography in Chronic Lymphocytic Leukemia Patients: Results of a Phase I Study N Hovhannisyan, SP Chantepie, M Ibazizene, A Manrique, O Reman, ... Blood 126 (23), 5267, 2015 | 1 | 2015 |
| [18 F]-Fludarabine Positron Emission Tomography in Diffuse Large B-Cell Lymphoma (DLBCL) Patients: Results of a Phase I Study SP Chantepie, N Hovhannisyan, S Guillouet, A Manrique, O Reman, ... Blood 126 (23), 3917, 2015 | 1 | 2015 |
| 10-day decitabine versus 3+ 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial M Lübbert, PW Wijermans, M Kicinski, S Chantepie, ... The Lancet Haematology 10 (11), e879-e889, 2023 | 4 | 2023 |
| 10-day decitabine versus intensive chemotherapy followed by transplantation in fit AML patients aged≥ 60 years: health-related quality of life outcomes of the randomized phase … F Efficace, GA Huls, M Kicinski, WJFM Van Der Velden, R Noppeney, ... Blood 140 (Supplement 1), 1281-1283, 2022 | 1 | 2022 |
| 10-day decitabine vs. standard induction, followed by allogeneic stem cell transplantation (HSCT) in AML patients>= 60 years: a randomized phase III intergroup study by the … M Luebbert, P Wijermans, M Kicinski, S Chantepie, W Van der Velden, ... ONCOLOGY RESEARCH AND TREATMENT 45 (SUPPL 2), 264-264, 2022 | | 2022 |
| 18F-fludarabine PET for lymphoma imaging: first-in-humans study on DLBCL and CLL patients S Chantepie, N Hovhannisyan, S Guillouet, JP Pelage, M Ibazizene, ... Journal of Nuclear Medicine 59 (9), 1380-1385, 2018 | 18 | 2018 |
| 290 WT1 expression level in peripheral blood: an early marker of myelodysplastic syndromes evolution? S Bustany, D Naguib, S Cheze, M Malet, S Chantepie, X Troussard Leukemia Research, S114, 2011 | | 2011 |
| 5‐Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy S Ivanoff, B Gruson, SP Chantepie, E Lemasle, L Merlusca, V Harrivel, ... American Journal of Hematology 88 (7), 601-605, 2013 | 54 | 2013 |
| A 16‐month‐long experience of COVID‐19 in allogeneic haematopoietic stem cell transplantation recipients: An SFGM‐TC multicentre cohort study A Xhaard, C Xhaard, MT Rubio, A Berceanu, C Botella‐Garcia, T Coman, ... British Journal of Haematology 201 (6), 1066-1071, 2023 | 2 | 2023 |
| A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia L Fenwarth, X Thomas, S De Botton, N Duployez, JH Bourhis, A Lesieur, ... Blood, The Journal of the American Society of Hematology 137 (4), 524-532, 2021 | 41 | 2021 |
| A Phase 2 Study of Ponatinib for Prevention of Relapse after Allotransplantation in FLT3-ITD+ AML Patients: The Ponallo Trial P Chevallier, A Thiebaut, S François, S Chantepie, MT Rubio, ... Blood 142, 4957, 2023 | | 2023 |
| A restrictive strategy reduces the number of transfused packed red blood cells in allograft recipients JB Mear, S Chantepie, AC Gac, A Bazin, O Reman Blood, The Journal of the American Society of Hematology 124 (21), 5106-5106, 2014 | 3 | 2014 |
| A RESTRICTIVE TRANSFUSION STRATEGY ALLOWS A REDUCTION IN THE NUMBER OF TRANSFUSED PACKED RED BLOOD CELLS: RESULTS OF A PILOT STUDY JB Mear, SP Chantepie, AC Gac, A Bazin, O Reman BONE MARROW TRANSPLANTATION 49, S503-S503, 2014 | | 2014 |
| Acquired Von Willebrand Syndrome Associated with B Cell Chronic Lymphoproliferative Disorders. Results from a Prospective Observational Study JB Rabec, P Gautier, X Troussard, AC Gac, S Chantepie, M Macro, ... Blood 124 (21), 1509, 2014 | | 2014 |
| Acute myeloid leukemia and antifungal prophylaxis era: compliance of AML centers, invasive fungal infection (IFI) classification, IFI incidence and AML outcomes from ALFA 2007 … M Michallet, M Sobh, S Morisset, A Deloire, E Raffoux, S De Botton, ... Blood 134, 2618, 2019 | 1 | 2019 |
| Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results C Gardin, C Pautas, E Fournier, R Itzykson, E Lemasle, JH Bourhis, ... Blood advances 4 (9), 1942-1949, 2020 | 66 | 2020 |
| Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation R Kim, N Boissel, A Touzart, T Leguay, F Thonier, X Thomas, E Raffoux, ... Leukemia 34 (7), 1730-1740, 2020 | 27 | 2020 |
| Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy … J Gauthier, S Chantepie, K Bouabdallah, E Jost, S Nguyen, AC Gac, ... Bulletin du Cancer 104 (12S), S131-S135, 2017 | 3 | 2017 |
| Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) J Gauthier, S Chantepie, K Bouabdallah, E Jost, S Nguyen, AC Gac, ... Bulletin du Cancer 104 (12S), S121-S130, 2017 | | 2017 |
| Allogeneic hematopoietic cell transplantation for Hodgkin's disease, mantle cell lymphoma and other rare entities: Guidelines from the Francophone Society of Bone Marrow … J Gauthier, S Chantepie, K Bouabdallah, E Jost, S Nguyen, AC Gac, ... Bulletin du Cancer 104 (12S), S112-S120, 2017 | 3 | 2017 |
